Microbot Medical Increases Rate Of Enrollment In ACCESS-PVI Trial, 80% Of Patients Have Completed Follow Period And Co Says On Track For FDA 510(k) Submission By End Of 2024
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical has accelerated the enrollment rate in its ACCESS-PVI trial, with 80% of patients having completed the follow-up period. The company is on track for an FDA 510(k) submission by the end of 2024.
September 30, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical has increased the enrollment rate in its ACCESS-PVI trial, with 80% of patients completing the follow-up period. The company is on track for an FDA 510(k) submission by the end of 2024, which could positively impact its stock.
The accelerated enrollment and high follow-up completion rate in the ACCESS-PVI trial indicate progress towards regulatory approval. The planned FDA 510(k) submission by the end of 2024 suggests potential future product commercialization, likely boosting investor confidence and positively impacting MBOT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100